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IL-23 produced by CNS-resident cells controls T cell
encephalitogenicity during the effector phase of experimental
autoimmune encephalomyelitis
Abstract
CNS-resident cells, in particular microglia and macrophages, are a source of inflammatory cytokines
during inflammation within the CNS. Expression of IL-23, a recently discovered cytokine, has been
shown to be critical for the development of experimental autoimmune encephalomyelitis (EAE) in mice.
Expression of the p40 subunit of IL-12 and IL-23 by microglia has been shown in situ and in vitro, but
direct evidence for a functional significance of p40 expression by CNS cells during an immune response
in vivo is still lacking. Here we report that p40 plays a critical role in maintaining encephalitogenicity
during the disease course. By using irradiation bone marrow chimeras, we have generated mice in which
p40 is deleted from the CNS parenchyma but not the systemic immune compartment. Our studies show
that p40 expressed by CNS-endogenous cells is critical for the development of myelin oligodendrocyte
glycoprotein-induced EAE. In spite of the reduced clinical disease, the absence of p40 from the CNS has
little impact on the degree of inflammation. Expression profiles of the CNS lesions show an increase in
Th2 cytokines when compared with mice that develop EAE in the presence of CNS IL-12 and/or IL-23.
Taken together, our data demonstrate that p40 expression by CNS-resident cells forms the basis for the
Th1 bias of the CNS.
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Introduction
The last year has witnessed a major change in focus
regarding the role of IL-12 in inflammation. Once con-
sidered a major mediator in the development of exper-
imental autoimmune encephalomyelitis (EAE), it has
now been reported by a number of laboratories that 
IL-12 is not essential in the development of EAE or of
a number of other inflammatory disorders (1–3). Con-
fusion as to the role of IL-12 in inflammation arose due
to the use of the common IL-12 p40 subunit by a pre-
viously unknown cytokine, IL-23 (4). IL-12 is a 70-kDa
heterodimer consisting of a p35 and a p40 subunit (5).
Recently we and others have shown that the IL-12 p40
subunit is indeed required for the induction of EAE in
mice, but that the p35 subunit and thus IL-12 was not
necessary for disease induction via active immuniza-
tion with myelin oligodendrocyte glycoprotein (MOG)
peptide in CFA (1). The explanation for this surprising
observation was that another p40-containing cytokine
was critical for EAE. In this context, IL-23, a newly iden-
tified p40/p19 heterodimeric cytokine, has been shown
to be the critical mediator in the pathogenesis of EAE.
Indeed, p19–/– mice have recently been demonstrated to
be completely resistant to the induction of MOG35–55
peptide–induced EAE, confirming that IL-23 rather
than IL-12 is responsible for the generation of
encephalitogenic cells (3).
The dramatic changes in our understanding of the
role of IL-12 and IL-23 in EAE have generated many
new questions. During the effector phase of MS and in
EAE, cells residing in the CNS have been shown to pro-
duce p40. Windhagen et al. found the p40 subunit of
IL-12 and IL-23 produced by macrophages/microglia
in MS plaques (6). During EAE, p40 is expressed with-
in the CNS, and its levels appear to correlate with dis-
ease severity (7). In vitro, both human and murine
microglia have been shown to produce p40 as well as
bioactive IL-12 in response to engagement of CD40 or
toll-like receptors (8–10). However, at this time there is
no compelling evidence for a functional role of
microglia-derived p40 in EAE. Cua and coworkers have
shown that resident microglia and infiltrating macro-
phages express mRNA for p19, and have further shown
that virus-mediated expression recombinant of IL-23
within the CNS can support EAE in p19–/– mice (3).
These observations pose the important question of
whether production of IL-23 by microglial cells or by
CNS-infiltrating macrophages is critical to the devel-
opment of this inflammatory disease.
In this report, we present data demonstrating that
p40 produced within the CNS by resident microglial
cells is critical for conserving the encephalitogenicity
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in a population of MOG peptide–reactive lympho-
cytes. By using irradiation BM chimeras, we have gen-
erated mice in which p40 is deleted from the CNS
parenchyma but not the systemic immune compart-
ment. Our studies show that p40 expressed by CNS-
endogenous cells is critical for the development of
MOG-induced EAE.
Methods
Mice. Female C57BL/6 and CD45 congenic C56BL/
6-Ly5.2 mice were obtained from the National Cancer
Institute (Frederick, Maryland, USA). Homozygous
IL-12 p35–/– and IL-12 p40–/– C57BL/6 mice were orig-
inally purchased from The Jackson Laboratory (Bar
Harbor, Maine, USA) and bred in-house under
pathogen-free conditions.
Irradiation BM chimeric mice. BM-donor mice were
euthanized using CO2 and BM cells were isolated by
flushing femur and tibia bones with HBSS. BM was
filtered through a 100-µm cell strainer and cells were
washed with BSS. CD45 congenic recipient mice were
lethally irradiated (12 Gy in a split dose) and intra-
venously injected with 2 × 107 BM cells. Engraftment
took place over 6–8 weeks of recovery. Mice were bled
retro-orbitally to ensure more than 95% engraftment
of blood leukocytes. We have previously reported that
this protocol allows us to generate mice in which the
APC compartment of the CNS and of the immune
system can be completely separated (11).
Peptides and Ab’s. MOG35–55 peptide (MEVGWYRSPF-
SRVVHLYRNGK) was obtained from Research Genet-
ics (Huntsville, Alabama, USA). For cytofluorometric
analysis, the antibodies against the following were
used: CD45-phycoerythrin (CD45-Pe), CD11b-FITC
(Mac1), CD4-biotin, GR-1–biotin, CD8-biotin, and
NK1.1-biotin. Biotin labels were visualized using strep-
tavidin-allophycocyanin (Pharmingen, La Jolla, Cali-
fornia, USA). All Ab’s were obtained from Pharmingen.
Induction of EAE. For active immunization, 5- to 8-
week-old female C57BL/6 or p40–/– mice (13- to 16-
week-old BM chimeric mice) were immunized subcu-
taneously with 200 µg of MOG35–55 peptide emulsified
in CFA supplemented with 2 mg/ml of Mycobacterium
tuberculosis (Difco Laboratories, Detroit, Michigan,
USA). The mice received intraperitoneal injections with
250 ng pertussis toxin (Sigma-Aldrich, St. Louis, Mis-
souri, USA) at the time of immunization and 48 hours
later. After 7 days, the mice received an identical boost-
er immunization with MOG peptide in CFA without
pertussis toxin. Clinical disease usually commences
between day 12 and day 18 after immunization.
For adoptive transfer, donor mice were immunized
subcutaneously with 200 µg MOG35–55 in CFA sup-
plemented with 500 µg Mycobacterium tuberculosis.
Immediately after immunization and 2 days later, the
mice received 250 ng of pertussis toxin. Eleven days
after immunization, the mice were sacrificed, spleens
were removed and homogenized, and red blood cells
were lysed. The cells were cultured for 4 days in RPMI
1640 supplemented with 10% FCS (both obtained
from BioWhittaker Inc., Walkersville, Maryland,
USA), 10 µg/ml of MOG peptide, and 2.5 ng/ml of
recombinant IL-12 (PeproTech Inc., Rocky Hill, New
Jersey, USA). The cells were harvested, and dead cells
were removed by Ficoll (Sigma-Aldrich) centrifuga-
tion. Cells were then washed and injected into recipi-
ent mice (5 × 106 to 2.5 × 107 cells/mouse). Animals
received 250 ng/mouse pertussis toxin on day 0 and
day 2 after transfer. Clinical disease usually com-
mences 6–10 days after cell transfer.
Clinical evaluation. The mice were scored four times
per week as follows: 0, no detectable signs of EAE; 0.5,
distal limp tail; 1, complete limp tail; 1.5, limp tail and
hind limb weakness; 2, unilateral partial hind-limb
paralysis; 2.5, bilateral partial hind-limb paralysis; 3,
complete bilateral hind-limb paralysis; 3.5, complete
Figure 1
Adoptive transfer of MOG-reactive lymphocytes into WT and p40–/–
recipients. MOG-reactive lymphocytes were generated in WT mice
and harvested as described. Cells (2.5 × 107, represented by dia-
monds, or 1.25 × 107, represented by squares) were injected into WT
(filled symbols) or p40–/– (open symbols) recipients. Clinical disease
was monitored, and the difference between WT and p40–/– mice 3
days after disease onset was significant (*P < 0.05, #P < 0.01) as
assessed using a nonpaired Student’s t test. Data shown are from one
representative experiment of at least three individual experiments
with at least five mice per group.
Table 1
EAE induced by adoptive transfer of encephalitogenic lymphocytes
Group Incidence Mean day of disease onsetA Mean maximal clinical scoreA
WT + 2.5 × 107 MOG-reactive cells 6/6 100% 8.3 3.0
WT + 1.25 × 107 MOG-reactive cells 5/6 83.33% 11.2 2.9
p40–/– + 2.5 × 107 MOG-reactive cells 2/5 40.00% 11.5 2.4
p40–/– + 1.25 × 107 MOG-reactive cells 2/5 40.00% 11.5 1.9
ADiseased animals only.
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hind-limb paralysis and unilateral forelimb paralysis;
4, total paralysis of fore and hind limbs (score greater
than 4 to be euthanized); 5, death.
Histology. Mice were euthanized with CO2. They were
then perfused with PBS and the spinal column of each
mouse was removed and fixed in 10% buffered forma-
lin. The spinal cord was dissected and paraffin embed-
ded prior to staining with H&E to assess infiltration.
Flow cytometry. Mice were euthanized with CO2 and
spinal cords were removed by flushing the spinal col-
umn with sterile BSS. The brain was dissected to isolate
the brain stem. Both tissues were homogenized and
strained through a 100-µm nylon filter (Fisher Scientif-
ic Co., Pittsburgh, Pennsyl-
vania, USA). After centrifu-
gation, the cell suspension
was resuspended in 37%
isotonic Percoll and under-
laid with 70% isotonic Per-
coll. The gradient was cen-
trifuged at 600 g for 25
minutes at room tempera-
ture. The interphase cells
were collected and exten-
sively washed prior to
staining. For flow cytome-
try, the cells were stained
with primary Ab’s for 30
minutes at 4°C, washed,
and incubated with strep-
tavidin-allophycocyanin
(Pharmingen) for 15 min-
utes. The cells were washed
and analyzed using a FACS-
Calibur system and Cell-
Quest software (Becton,
Dickinson and Co., San
Jose, California, USA). Data
analysis was performed
using WinMDI 2.8 soft-
ware (Scripps Research
Institute, La Jolla, Califor-
nia, USA).
Recall responses. Mice
were primed by flank
injections of MOG pep-
tide in CFA. After 5 days, the axillary and
inguinal lymph nodes were removed and
homogenized. Lymph node cells (5 × 105)
were placed in triplicate in a 96-well plate
and pulsed with different amounts of
MOG peptide or the irrelevant peptide
myelin proteolipid protein (PLP139–151;
Research Genetics) as a control. After 48
hours, cells were pulsed with [3H]thymi-
dine (NEN Life Science Products,
Boston, Massachusetts, USA) and incu-
bated for an additional 15 hours before
cells were harvested. Thymidine incorpo-
ration was assessed using a Filtermate harvester and
a TopCount NXT microplate scintillation and lumi-
nescence counter (both from Packard Bioscience Co.,
Meriden, Connecticut, USA). For cytokine analysis,
sister cultures were harvested 48 hours later, and cul-
ture supernatants were analyzed by ELISA for IFN-γ
and IL-2 (Pharmingen).
Real-time PCR. RNA was extracted from spinal cords
of mice with EAE as described (11). Briefly, the spinal
column was flushed with ice-cold HBSS and the cords
were homogenized in Trizol reagent (Invitrogen Corp.,
Carlsbad, California, USA). RNA was extracted follow-
ing the manufacturer’s instructions. The samples were
Figure 2
Infiltration of leukocytes into the CNS of WT and p40–/– mice. Animals were sacri-
ficed 5 days after disease onset, and spinal cord inflammation was assessed by H&E
staining (magnification, ×100). (a) Naive WT control. Adoptively transferred WT
(b) or p40–/– (c) recipients.
Figure 3
Inflammatory makeup of infiltrating cells. Animals were sacrificed at day 24 after injection with
encephalitogenic lymphocytes, and spinal cord inflammation was assessed by flow cytometry. Infiltrates
were stained with antibodies against CD45, CD11b, CD4, CD8, and GR-1 as shown above. (a) Densi-
ty plots of CNS cells double-stained with CD45 and CD11b. Histograms show staining with CD45-Pe.
The marker M1/R2 represents CNS-infiltrating cells. (b) Histograms of CNS-infiltrating cells (R2) iso-
lated from WT and p40–/– mice injected with encephalitogenic lymphocytes. The filled histograms show
staining with anti–GR-1, anti-CD4, and anti-CD8 mAb’s. The dotted histograms represent the appro-
priate isotype controls. Percentage of positive cells is shown above the marker line (M1).
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treated with DNase using DNA AWAY (Molecular Bio-
products Inc., San Diego, California, USA), and 5 µg of
RNA was transcribed into cDNA using oligo-dT
primers and the SuperScript II RT kit (Invitrogen
Corp.). Twelve nanograms cDNA per well was trans-
ferred into iCycler 96-well plates (Bio-Rad Laboratories
Inc., Hercules, California, USA), and SuperMix-UDG
master mix containing Taq polymerase (Invitrogen
Corp.) was added according to the manufacturer’s
instructions. The following primer-probe pairs were
used: GATA-3: sense, AGAACCGGCCCCTTATCAA; anti-
sense, AGTTCGCGCAGGATGTCC; probe, CCAAGC-
GAAGGCTGTCGGCAG. IFN-γ: sense, GCATTCATGAG-
TATTGCCAAG; antisense, GGTGGACCACTCGGATGA;
probe, ACCCACAGGTCCAGCGCCA. IL-4: sense,
ACAGGAGAAGGGACGCCAT; antisense, GAAGCCC-
TACAGACGAGCTCA; probe, TCCTCACA-
GCAACGAAGAACACCACA. T-BET: sense,
CAACAACCCCTTTGCCAAAG; antisense,
TCCCCCAAGCAGTTGACAGT; probe, CCG-
GGAGAACTTTGAGTCCATGTACGC. TNF-α:
sense, CATCTTCTCAAAATTCGAGTGACAA;
antisense, TGGGAGTAGACAAGGTACA-
ACCC; probe, CACGTCGTAGCAAACCAC-
CAAGTGGA.
PCR was performed on an iCycler with
optical unit (Bio-Rad Laboratories Inc.).
The PCR conditions were 5 minutes of
denaturing at 95°C followed by 40 cycles
of 15 seconds at 95°C and 45 seconds at
63°C. Amplicon accumulation was meas-
ured during the annealing phase. Reaction
efficiency for each primer was 100% ± 10%,
based on the slope generated by standard
curves using specific cloned amplicons. A
standard curve was generated for each 96-
well plate using a plasmid containing the
β-actin amplicon. Data were analyzed
using iCycler analysis software version 2.3.
Results
p40-deficient mice display decreased EAE
severity upon adoptive transfer of MOG-reac-
tive cells. We and others have previously
shown that p40–/– and p19–/–, but not
p35–/– mice, are completely resistant to
the induction of EAE upon active immu-
nization with myelin antigen (1–3).
Therefore, whether one examines inflam-
mation in p40–/– or p19–/– mice, the phenotype is
exclusively due to the lack of IL-23. We wanted to
extend these studies to assess the role and function
of p40 during the effector phase of EAE. In order to
do so, we adoptively transferred MOG-reactive lym-
phocytes (generated in WT mice) into either p40–/– or
WT mice. Figure 1 and Table 1 show that p40–/– mice
develop EAE with significantly delayed kinetics and
decreased severity (P < 0.01), indicating that host-
expressed p40 is involved in the maintenance of
encephalitogenicity during the effector phase of EAE.
These data are consistent with the observations of
Cua and colleagues have shown that intracerebral
administration of IL-23 after disease onset can
restore disease in p19–/– mice (3).
p40 drives encephalitogenicity but not inflammation. In
spite of the reduced clinical phenotype of p40–/– mice
upon adoptive transfer of MOG-reactive lympho-
cytes, histological analysis (Figure 2) revealed signif-
icant inflammation in the spinal cords of p40–/– mice
that was comparable to that of WT mice with signif-
icantly more severe EAE. This finding supports the
notion that p40 is not absolutely required for the
infiltration of inflammatory cells into the CNS, but
rather alters the degree of encephalitogenicity upon
entry into the CNS. For a more quantitative analysis
Figure 4
BM transfer fully reconstitutes the host’s ability to drive Th1 immunity. After 2
months of recovery, BM chimeric mice were immunized with MOG peptide in CFA
and lymph nodes were removed 5 days later. Recall proliferation (a), IL-2 (b), and
IFN-γ secretion (c) in response to either 100 µg MOG peptide or irrelevant myelin
proteolipid protein peptide was assessed in vitro. White bars, medium alone; black
bars, 100 µg MOG peptide; gray bars, 100 µg PLP peptide. +, WT; –, p40–/–; arrows
indicates the transfer of BM. (d) After BM transplant, mice (diamonds, p40+/+ →
p40+/+; squares, p40+/+ → p40–/–; ×, p40–/– → p40+/+; triangles, p40–/– → p40–/–)
were allowed to recover for 2 months, then immunized with MOG35–55 in CFA as
described and scored for clinical disease. In all experiments, the disease score
between the susceptible p40+/+ → p40+/+ and p40+/+ → p40–/– mice was significant-
ly different as assessed using a nonpaired Student’s t test (#P < 0.01). Shown is a
representative of four individual experiments.
Table 2
Phenotype of BM chimeras
BM donor Recipient mouse p40 expression
WT WT Whole body
WT p40–/– Immune compartment
p40–/– WT CNS parenchyma
p40–/– p40–/– Null
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of CNS infiltrates, 5 days after disease onset, the
recipient mice were euthanized, and infiltration into
the spinal cord was measured by flow cytometry. Fig-
ure 3a shows that the absence of p40 in the recipient
does not significantly alter the degree of inflamma-
tion. Both WT and p40–/– mice immunized with
MOG35–55 peptide display a high number of CD45hi
infiltrating cells compared with nonimmunized
mice. We did not observe an overt change in the cel-
lular profile of infiltrating cells with regard to the
percentage of CD4+ or CD8+ T cells, macrophages, or
polymorphonuclear cells as assessed by flow cytom-
etry (Figure 3b). The number of NK cells or NK T
cells was negligible as assessed by NK1.1 staining (not
shown). The data indicate that the quality of the CNS
immune response is different in the WT than in the
p40–/– CNS, but that the differences do not lie in the
composition of the infiltrating cells.
Production of p40 CNS-endogenous cells is critical for the
induction of EAE upon active immunization. We have pre-
viously shown that CNS-endogenous cells, most like-
ly microglia, control the extent of inflammation in
EAE via CD40 (11). Mice in which CD40 is not
expressed within the CNS show a decrease in inflam-
matory infiltrates and a paucity in early chemokine
expression by CNS-resident cells. In order to assess
the role of p40 expressed by cells within the CNS dur-
ing the effector phase of EAE, we selectively expressed
p40 within the CNS using irradiation BM chimeras.
Following irradiation and BM reconstitution, the
peripheral APC compartment is comprised entirely of
BM-donor–derived cells, whereas 100% of CNS-resi-
dent microglia remain of host origin (11). We gener-
ated BM chimeras by transferring p40–/– or WT BM
into irradiated p40–/– and WT recipients (Table 2). To
confirm the phenotype of the reconstituted peripher-
al APC compartment, we immunized these mice and
determined the capacity of APCs in the periphery to
support Th1 responses in a recall assay. Figure 4, a
and b, shows that the antigen-induced T cell prolifer-
ation and production of IL-2 and IFN-γ are intact in
WT → WT and WT → p40–/– mice. In contrast, in
p40–/– → WT and p40–/– → p40–/– mice, T cells were
incapable of inducing IFN-γ secretion.
Using this panel of mixed BM chimeric mice, mice
were immunized with MOG35–55 in CFA and disease
development was assessed as described. Figure 4d and
Table 3 show that p40 produced by cells resident to the
CNS is essential for full disease development. In the
absence of CNS-derived p40 (WT → p40–/–), we saw a
marked delay in disease onset and a decrease in disease
severity. It is important to emphasize that while both
WT → p40+/+ and WT → p40–/– chimeras have an equiv-
alent capacity to generate peripheral Th1-type T cells,
the disease in the latter is compromised.
Th1 polarization by CNS-derived IL-12 p40. We wanted
to determine the impact of p40 expressed within the
CNS on the cytokine profile of the infiltrating lym-
phocytes. We immunized p40–/– BM chimeras with
MOG35–55 in CFA as described. The mice were sacri-
ficed at the first sign of clinical disease to extract
RNA from the spinal cords. Expression levels of Th1
and Th2 markers were assessed by real-time PCR
using hydrolysis probes (TaqMan) (Figure 5). The
data reveal that the infiltrates in p40–/– mice display
a Th2 polarized phenotype, whereas the WT mice
appear more Th1 biased. A similar trend could be
observed in p40–/– mice upon adoptive transfer (data
not shown). The data indicate that the encephalito-
genic potential of infiltrating lymphocytes is nur-
tured by p40 expressed within the CNS.
Table 3
EAE in BM chimeras induced by active immunization with MOG peptide (see Figure 4d)
Group Incidence Mean day of disease onsetA Mean maximal clinical scoreA
WT → WT 4/5 80% 17.2 4
WT → IL-12 p40–/– 4/6 67% 23.3 2.1
IL-12 p40–/– → IL-12 p40–/– 0/3 0%
IL-12 p40–/– → WT 0/4 0%
ADiseased animals only.
Figure 5
Expression profile of inflamed spinal cords. RNA was isolated as
described from inflamed spinal cords 24 days after immunization.
Real-time RT-PCR analysis was performed by measuring amplicon
accumulation using TaqMan probes (Qiagen Inc.) (black bars, WT;
white bars, p40–/–). Data are expressed as arbitrary units based on
the standard curve of triplicate wells ± SD. Shown is a representative
of at least three individual experiments. Levels of β-actin mRNA were
similar in both samples, and other mRNA species levels were nor-
malized to β-actin.
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Discussion
The goal of our study was to determine the role of
CNS-expressed p40 during the effector phase of EAE.
Upon adoptive transfer of fully primed and activated
WT MOG-reactive lymphocytes into p40–/– mice, we
observed a marked delay in disease onset and a signif-
icant decrease of disease severity when compared with
WT mice. Interestingly, although the degree of clinical
symptoms was modest, the spinal cords of these mice
still showed a large number of inflammatory infil-
trates. Upon entry of leukocytes into the CNS, resident
cells, in particular microglial cells, become activated
and secrete a variety of proinflammatory factors
including IL-12 and IL-23 (3, 9). We hypothesized that
it is the CNS microenvironment that regulates T cell
behavior during CNS inflammation in both EAE and
MS. We generated BM chimeras in order to assess the
role of p40 expressed by CNS-endogenous cells (radio-
resistant compartment), while having an immune
compartment fully capable of supporting T cell acti-
vation, Th1 polarization, and encephalitogenicity.
After active immunization of these mice, in the
absence of p40 expressed within the CNS, we observed
only subclinical EAE. In the absence of p40 from the
CNS, autoreactive lymphocytes still infiltrate the CNS,
but do not fully develop their encephalitogenic poten-
tial. This finding is consistent with a recent report
showing that mice deficient in the p19 subunit of 
IL-23 develop clinical EAE only upon delivery of IL-23
into the CNS. Peripheral complementation was insuf-
ficient to break EAE resistance (3). Furthermore, CNS-
infiltrating inflammatory macrophages have been
shown to express p19 and thus IL-23 at levels compa-
rable to those expressed by CNS-resident microglia (3).
However, the amount of IL-23 produced by CNS-
invading cells alone is insufficient to drive a fulminant
encephalitogenic Th1 response. It appears that the
CNS residents participate in Th polarization and that
this participation is a critical determinant in the dis-
ease pathogenesis.
To assess the impact of p40 secretion by CNS-resi-
dent cells on the inflammatory response, we evaluat-
ed the expression profile of Th1/2-associated genes
expressed by CNS-infiltrating T cells. Expression
analysis of spinal cords for Th1 and Th2 markers
revealed that in the absence of p40 from the CNS, a
shift from a Th1 profile toward a Th2/0 polarized
phenotype was induced.
The Th1/2 paradigm of inflammation in EAE and MS
is challenged by gene-deletion studies showing that EAE
can develop irrespective of Th1 cytokines (12–16) and
Th1-inducing cytokines (e.g., IL-12). Thus, one cannot
assume that the expression of Th1 markers correlates
with encephalitogenicity. Nonetheless, it appears that
continued exposure of lymphocytes to IL-23 at the site
of inflammation is critical for the sustained expression
of Th1-associated genes. As for MS, therapeutic inter-
vention by targeting the IL-12/23 pathway may provide
a powerful inhibitor of disease progression without the
side effects of broad immune suppression.
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